首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and anticancer evaluation of novel 2-cyclopropylimidazo(2,1-b)(1,3,4)-thiadiazole derivatives.
【24h】

Synthesis and anticancer evaluation of novel 2-cyclopropylimidazo(2,1-b)(1,3,4)-thiadiazole derivatives.

机译:新型2-环丙基咪唑并(2,1-b)(1,3,4)-噻二唑衍生物的合成和抗癌评估。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of 2,5,6-trisubstituted imidazo[2,1-b][1,3,4]-thiadiazole derivatives 4(a-k) have been prepared by reaction of 2-amino-5-cyclopropyl-1,3,4-thiadiazole and an appropriate phenacyl bromide. Further 5-bromo 5(a-k) and 5-thiocyanato 6(a-k) derivatives were synthesized in order to study the effect of these substituents on antitumor activity. Structures of these compounds were established by IR, (1)H NMR, (13)C NMR and Mass spectroscopy. Seven compounds were granted NSC code at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10(-5) M) in full NCI 60 cell panel. Among the compounds tested, 5-bromo-6-(4-chlorophenyl)-2-cyclopropylimidazo[2,1-b][1,3,4]thiadiazole 5b (NSC D-96022/1) was found to be the most active candidate of the series at five dose level screening with degree of selectivity toward Leukemic cancer cell line.
机译:通过2-氨基-5-环丙基-1,3的反应制备了一系列2,5,6-三取代的咪唑并[2,1-b] [1,3,4]-噻二唑衍生物4(ak), 4-噻二唑和适当的苯甲酰溴。为了研究这些取代基对抗肿瘤活性的影响,还合成了5-溴5(a-k)和5-硫氰酸根6(a-k)衍生物。这些化合物的结构通过IR,(1)H NMR,(13)C NMR和质谱确定。七种化合物在美国国家癌症研究所(NCI)被授予NSC代码,以在完整的NCI 60细胞组中以单一高剂量(10(-5)M)进行抗癌活性。在测试的化合物中,发现5-溴-6-(4-氯苯基)-2-环丙基咪唑并[2,1-b] [1,3,4]噻二唑5b(NSC D-96022 / 1)最多在对白血病细胞株具有选择性的五个剂量水平筛选中,该系列的有效候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号